Engene Holdings INC Form 4 insider transactions

Alexander Julian Nichols, Chief Strategy & Ops. Ofc at enGene Holdings Inc., reports the acquisition of stock options.

Lee Giguere, Chief Legal Officer and Corporate Secretary of enGene Holdings Inc., acquired stock options for 250,000 common shares on January 29, 2025.

enGene Holdings' Chief Financial Officer, D. Ryan Daws, was granted 280,000 stock options on January 29, 2025.

Anthony T. Cheung, Chief Scientific Officer of enGene Holdings Inc., reports the acquisition of stock options.

Ronald Harold Wilfred Cooper, CEO & President of enGene Holdings Inc., acquired 850,000 stock options on January 29, 2025, according to a Form 4 filing.

Forbion Growth Opportunities Fund I Cooperatief U.A. acquired 561,797 common shares of enGene Holdings Inc. in a private placement and disposed of 3,032,430 shares.

Chief Scientific Officer Anthony T. Cheung acquired 100,000 stock options in enGene Holdings Inc. on October 21, 2024.

Joan Connolly, Chief Technology Officer of enGene Holdings Inc., was granted a non-qualified stock option for 210,000 shares on October 21, 2024.

Forbion Growth Opportunities Fund I reports multiple purchases of enGene Holdings Inc. common shares between December 2023 and October 2024, increasing its holdings.

enGene Holdings CEO Ronald Cooper recently purchased 10,000 shares of the company's common stock at an average price of $5.70.

Chief Medical Officer Raj Som Pruthi received stock options for 110,000 common shares in enGene Holdings Inc. on July 24, 2024.

CEO Ronald Cooper was granted 1,250,000 stock options in enGene Holdings Inc. on July 22, 2024, according to a Form 4 filing.

Director Lota S. Zoth acquired 20,000 stock options in enGene Holdings Inc. on June 15, 2024.

Director Paul J Hastings acquired stock options for 40,000 common shares of enGene Holdings Inc. on June 15, 2024.

Director Joustra Wouter of enGene Holdings Inc. reports the acquisition of stock options on June 15, 2024.

Director Richard M. Glickman reports the acquisition of stock options for 20,000 common shares of enGene Holdings Inc. on June 15, 2024.

Director Jasper Bos acquired 20,000 stock options in enGene Holdings Inc. on June 15, 2024.

Director Gerald A. Brunk acquired options to purchase 20,000 common shares of enGene Holdings Inc.

Richard M. Glickman, a director of enGene Holdings Inc., exercised stock options to acquire 120 common shares at a price of $0.89 on May 28, 2024.

Fonds de Solidarité des Travailleurs du Québec reports selling shares of enGene Holdings Inc. between April 18 and April 22, 2024, reducing its holdings.

Director Lota S. Zoth reports acquisition of stock options in enGene Holdings Inc.

Anthony T. Cheung, Chief Technology Officer of enGene Holdings Inc., exercised stock options to acquire 52,940 common shares at $0.89 on March 18, 2024.

Lee Giguere, Chief Legal Officer and Corporate Secretary of enGene Holdings Inc., acquired stock options for 225,000 common shares on March 15, 2024.